Dr. Won Jin Ho presented a talk as part of the Immunology Neighborhood Seminar on “Overcoming the tumor immune ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, today provided details from the abstracts featuring pelareorep ...

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...

in PDAC. The difference is significant (p < 0.001). (B) boxplots depicting K102-Env levels for 24 patients with distant metastases (M1) and 23 patients without distant metastases (M0) in HCC. The ...

developing novel immune strategies will continue to play a critical role in designing effective treatment modalities for those at high risk of recurrence and those with distant metastasis.

About GOBLET Cohort 5 The mFOLFIRINOX cohort of the Phase 1/2 GOBLET study is designed to evaluate newly diagnosed metastatic PDAC patients ... inducing anti-cancer immune responses and promotes ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

In the current study, scientists generate and analyze genomic, transcriptomic, and T-cell receptor sequencing data of metastatic PDAC patients to explore molecular and immune differences between ...

The role of GPR55 in cancer cells has been widely described, but its role in the immune TME is not well understood. Methods: We intended to uncover the role of GPR55 in tumor immunity in a model of ...

About GOBLET Cohort 5 The mFOLFIRINOX cohort of the Phase 1/2 GOBLET study is designed to evaluate newly diagnosed metastatic PDAC patients treated with pelareorep + mFOLFIRINOX with or without ...